Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R.I.T.E. for Hormone Refractory Prostate Cancer
NCT00176527Phase 2Terminated
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Nov 2002
- Primary completion
- Aug 2007
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isotretinoin, interferon alfa-2b, docetaxel and estramustine in prostate cancer (PCa), sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Response Rate (biochemical and measurable disease). Started Nov 2002; status: terminated.
02
Drugs
isotretinoininterferon alfa-2bdocetaxelestramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00176527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176527.